Circulating Tissue Factor Pathway Inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia-Reference-Cited by-同舟云学术

Circulating Tissue Factor Pathway Inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia

Published:2021-02 Issue: Volume:105 Page:32-40
ISSN:0143-4004
Container-title:Placenta
language:en
Short-container-title:Placenta

Author:

MacDonald Teresa M.^ORCID,Tong Stephen,Myers Jenny,Cannon Ping^ORCID,Nguyen Tuong-Vi,Keenan Emerson^ORCID,Murray Elizabeth,Harper Alesia^ORCID,Pritchard Natasha,Hannan Natalie J.,Dane Kirsten M.,Middleton Anna L.^ORCID,Kyritsis Valerie P.,Walker Susan P.,Kaitu’u-Lino Tu'uhevaha J.

Funder

Norman Beischer Medical Research Foundation

RANZCOG Research Foundation

National Health and Medical Research Council

Publisher

Elsevier BV

Subject

Developmental Biology,Obstetrics and Gynecology,Reproductive Medicine

Reference23 articles.

1. Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial;Chappell;Lancet,2019

2. The Untapped Potential of Placenta-Enriched Molecules for Diagnostic and Therapeutic Development;Whigham,2019

3. Structure and biology of tissue factor pathway inhibitor;Bajaj;Thromb. Haemostasis,2001